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We investigated the association between genetic variations in pharmacodynamic genes
and risperidone-induced increased prolactin levels in children and adolescents with autism
spectrum disorder (ASD). In a retrospective study, variants of pharmacodynamic genes
were analyzed in 124 ASD patients treated with a risperidone regimen for at least
3 months. To simplify genotype interpretation, we created an algorithm to calculate the
dopamine D2 receptor (DRD2) gene genetic risk score. There was no relationship between
prolactin levels and single SNPs. However, the H1/H3 diplotype (A2/A2-Cin/Cin-A/G) of
DRD2/ankyrin repeat and kinase domain containing 1 (ANKK1) Taq1A, DRD2 -141C indel,
and DRD2 -141A>G, which had a genetic risk score of 5.5, was associated with the
highest median prolactin levels (23 ng/ml). As the dose-corrected plasma levels of
risperidone, 9-OH-risperidone, and the active moiety increased, prolactin levels in
patients carrying the H1/H3 diplotype were signiﬁcantly higher than those of the other
diplotypes. DRD2 diplotypes showed signiﬁcantly high prolactin levels as plasma
risperidone levels increased. Lower levels of prolactin were detected in patients who
responded to risperidone. This is the ﬁrst system for describing DRD2 haplotypes using
genetic risk scores based on their protein expression. Clinicians should consider using
pharmacogenetic-based decision-making in clinical practice to prevent prolactin increase.
Keywords: risperidone, prolactin, autism spectrum disorder, genetic risk score, dopamine D2 receptor (DRD2)
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INTRODUCTION

4] genes, although not directly targeted by antipsychotic
medications, may inﬂuence neurotransmitter availability, and
thus contribute to the variability in treatment response
(Kirchheiner et al., 2007; Porcelli et al., 2012; Outhred et al.,
2016).
The anterior pituitary hormone prolactin has essential
physiological functions in the brain. Prolactin acts as a
neuropeptide, regulating neuroendocrine and emotional stress
responses (Torner, 2016). Serum prolactin levels may also reﬂect
the antipsychotic treatment response. Several clinical studies
(Zhang et al., 2002; Ates et al., 2015; Stern et al., 2018)
revealed that prolactin may mediate effects on the
neuropsychiatric response to risperidone. Zhang et al. (2002)
observed a signiﬁcant positive relationship between the reduction
rate of positive subscale scores of the Positive and Negative
Syndrome Scale (PANSS) and the change in prolactin levels
before and after treatment in chronic schizophrenia. Ates et al.
(2015) found that in patients with hyperprolactinemia, the
PANSS negative symptom scores were signiﬁcantly higher
than in patients without hyperprolactinemia (p  0.041).
Furthermore, several moderators and mediators affecting
risperidone response have been described (Stern et al., 2018),
and lower baseline levels of prolactin predict responder status in
autistic children. Additionally, genetic polymorphisms in the
prolactin (PRL) (Lee et al., 2007; Ivanova et al., 2017) and
prolactin receptor (PRLR) (Lee et al., 2007) genes may also
contribute to increased prolactin levels. The strongest
association was between a single SNP of PRL (A>T,
rs2244502) and prolactin levels, which showed higher
prolactin levels in T carriers than in A carriers. Patients with
hyperprolactinemia carried the G/G genotype of −1149 G>T
(rs1341239) in the PRL gene more frequently than patients
without hyperprolactinemia (p  0.009) (Ivanova et al., 2017).
Therefore, prolactin is a promising candidate biomarker for
risperidone response.
The impact of pharmacogenetics on increased prolactin levels
has not been well investigated. Stern et al. (2018) reported the
effect of hyperprolactinemia in pediatric ASD patients with
disruptive behaviors undergoing risperidone therapy.
Therefore, in this study we investigated the association
between genetic variations in pharmacodynamic genes and
risperidone-induced increases in prolactin levels in children
and adolescents with ASD.

Risperidone is an atypical antipsychotic used to treat autism
spectrum disorder (ASD). Its effect is mediated via dopamine D2
receptor and 5-hydroxytryptamine type 2A receptor antagonism
(Corena-McLeod, 2015). The US Food and Drug Administration
has approved risperidone for the treatment of irritability in
children and adolescents aged 5–16 years with ASD (Goel
et al., 2018). Risperidone has a more favorable safety and
efﬁcacy proﬁle than typical antipsychotic drugs (Peuskens
et al., 2014). Two clinical trials (McCracken et al., 2002; Shea
et al., 2004) established the efﬁcacy and tolerability of risperidone
in patients with ASD and showed that risperidone signiﬁcantly
attenuated disruptive behaviors compared with the placebo over
8 weeks, as measured by a reduction in the irritability subscale of
the aberrant behavior checklist (ABC) scores. The improvement
in the risperidone treatment group was higher (56.9–64.0%)
compared with that in the placebo group (14.1–31.0%)
(McCracken et al., 2002; Shea et al., 2004).
Several studies (Baumann et al., 2004; Riedel et al., 2005) have
explored the utility of plasma drug monitoring as a biomarker of
treatment response. Therapeutic drug monitoring can improve
the efﬁcacy and safety of risperidone. Plasma levels of 20–60 ng/L
of the active moiety lead to better clinical outcomes in adults with
schizophrenia (Baumann et al., 2004; Nazirizadeh et al., 2010).
Plasma levels of the active moiety in non-responders were
signiﬁcantly higher than in responders in a 6 weeks clinical
trial of risperidone treatment in schizophrenia patients (Riedel
et al., 2005). However, no therapeutic drug monitoring data are
available for pediatric patients with ASD treated with risperidone.
There is considerable variation in the response to risperidone
that may be explained, at least partly, by genetic variation in drug
targets. A polymorphism in the dopamine D2 receptor (DRD2)/
ankyrin repeat and kinase domain containing 1 (ANKK1) gene
(often referred to as the Taq1A polymorphism; rs1800497) was
associated with a clinical response in risperidone-treated ASD
patients (Nuntamool et al., 2017). The DRD2/ANKK1 Taq1A A2
or C allele (Sukasem et al., 2016) have been associated with high
dopamine receptor densities (Jonsson et al., 1999), which may
contribute to blocking dopaminergic activity. DRD2 -241A>G
(rs1799978), located in the 5′-promoter region of DRD2, may
contribute to increased expression levels. (Nyman et al., 2009).
DRD2 -141C insertion/insertion has been associated with high
prolactin levels in antipsychotic-treated male schizophrenia
(Zhang et al., 2011). Carriers of the dopamine D3 receptor
Gly/Gly allele (rs6280) showed signiﬁcantly better response
rates compared with the Ser/Ser genotype in children with
ASD (Firouzabadi et al., 2017). Genetic variation in the 5hydroxytryptamine type 2A receptor (HTR2A), 5hydroxytryptamine type 2C receptor (HTR2C), and ATP
binding cassette subfamily B member 1 genes also contribute
to clinical outcomes and are possible markers for predicting a
positive response to risperidone therapy in ASD (Correia et al.,
2010). Moreover, the dopamine transporter [DAT; also known as
solute carrier family 6 member 3 (SLC6A3)] and serotonin
transporter [5-hydroxytryptamine transporter-linked promoter
region (5-HTTLPR) also known as solute carrier family 6 member
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MATERIALS AND METHODS
Participants
ASD children and adolescents aged 3–18 years were recruited at
the Yuwaprasart Waithayopathum Child Psychiatric Hospital,
Samut Prakan, Thailand, in 2017 and 2018. All participants were
ethnic Thai. The clinical neuropsychiatric diagnosis was made
according to the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition criteria. The Ethics Committee of the
Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand
(MURA2017/556) and Yuwaprasart Waithayopathum Child
Psychiatric Hospital, Samut Prakan, Thailand approved the
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study. All participants or parents of the children signed an
informed assent or consent after the study objectives and
procedures were explained. Sociodemographic data (gender,
age at assessment, daily risperidone dosage, duration of
risperidone treatment, and concomitant medication) were
collected with a questionnaire. Patients were excluded if they
were receiving concomitant medication that could affect
risperidone metabolism (e.g., haloperidol, ﬂuoxetine,
paroxetine, carbamazepine, and phenytoin) or prolactin levels
(e.g., haloperidol, sertraline, and ﬂuoxetine).

high-performance liquid chromatography method (Puangpetch
et al., 2016; Vanwong et al., 2016). The active moiety levels were
calculated by summing the levels of risperidone and 9-OHrisperidone. Plasma drug levels of risperidone, 9-OHrisperidone, and active moiety were corrected by the daily
dose to give the dose-corrected risperidone (RIS C/D), dosecorrected 9-OH-risperidone (9-OH-RIS C/D), and dosecorrected active moiety (active moiety C/D).

Pharmacogenetic Testing
Genomic DNA was obtained from EDTA blood using the MagNa
Pure automated extraction system according to the
manufacturer’s instructions (Roche Diagnostics, Basel,
Switzerland). The DNA samples were subsequently genotyped
for the following sequence variations: DRD2/ANKK1 Taq1A
A2>A1 (rs1800497), DRD2 -141C indel (rs1799732), and
-241A>G (rs1799978); HTR2A -1438G>A (rs6311); HTR2C
-759C>T (rs3813929); and PRL 13096T>A (rs2244502), and
PRLR 163444A>C (rs37364). SNPs were selected based on
functional signiﬁcance (Kirchheiner et al., 2007; Correia et al.,
2010; Porcelli et al., 2012; Outhred et al., 2016; Firouzabadi et al.,
2017; Nuntamool et al., 2017) and minor allele frequencies of
>0.05 across the Asian population. All SNPs were genotyped
using the commercially available TaqMan Drug Metabolism
Genotyping assay (Life Technologies, Carlsbad, CA,
United States). Genotyping was carried out as recommended
by the manufacturer using a real-time PCR system (ViiA7,
Applied Biosystems, Life Technologies).
To determine the number of variable tandem repeats (VNTRs) of
DAT, 60 ng genomic DNA was ampliﬁed in 25 μl PCR reactions,
containing 2X Green PCR master mix (12.5 μl, BiotechRabbit,
Hennigsdorf, Germany), and 1 μl of each 10 μM primer (forward,
5′-TCCTTGCGGTGTAGGGAACG-3′; reverse 5′-CCAGGCAGA
GTGTGGTCTG-3′). Denaturation at 95°C for 2 min was followed
by 35 cycles of 95°C for 30 s, 65°C for 40 s, and 72°C for 1 min, and a
ﬁnal extension step at 72°C for 10 min. The fragment sizes were
263 bp (5 repeats), 423 bp (9 repeats), 463 bp (10 repeats), and
503 bp (11 repeats), respectively. For 5-HTTLPR, 8 µl PCR reactions
contained 4 µl KAPA 2GTM Fast ReadyMix (KAPA Biosystems,
Woburn, MA, United States), 0.6 μl of each 5 μM primer (forward,
5′-CACAAACATGCTCATTTAAGAAGTG-3′; reverse, 5′-AAA
GGAAATAGCAGTGACAAGTTTG-3′), and 20 ng genomic
DNA. PCR was initiated by a 2 min incubation at 95°C, which
was followed by 40 cycles of 95°C for 15 s, 62°C for 40 s, and 72°C for
30 s, and a ﬁnal extension at 72°C for 1 min. Amplicons representing
the short (733 bp) and long (777 bp) alleles were separated by 2%
agarose gel electrophoreses.

Study Protocol
The retrospective study included 124 ASD patients treated with a
risperidone-based regimen for at least 3 months. Serum prolactin
levels, plasma levels of risperidone, 9-OH-risperidone, and the
active moiety were measured, and the candidate genes were
genotyped. We also included 19 risperidone-naïve patients
who underwent a baseline assessment before starting
risperidone therapy. They were available for a follow-up
assessment 3–20 months after risperidone treatment was
started. At the ﬁrst and follow-up visits, assessments were
performed using ABC subscales and serum prolactin and
plasma drug levels.

Behavior Assessments
The ABC subscale assessment consisted of 58 items, divided into
the following ﬁve categories of behavior: irritability, agitation, and
crying (15 items); lethargy and social withdrawal (16 items);
stereotypic behavior (7 items); hyperactivity and non-compliance
(16 items); and inappropriate speech (4 items). The probands
were rated by a primary patient’s caregiver for the different
severity of behavior problems from zero (no problems) to
three (severe problems), with higher scores indicating
problems that were more severe (Narkpongphun and Charnsil,
2018b). The ABC-irritability subscale score is an accepted gold
standard for measuring irritability and aggression in medication
trials for ASD (Fung et al., 2016). We used the ABC-C Thai
version, which was created with a cross-cultural adaptation
method, has been validated, and is highly reliable
(Narkpongphun and Charnsil, 2018a). Patients with ASD were
divided into responders and non-responders according to the
reduction rate of the total ABC scores. Patients classiﬁed as
responders had a reduction rate of total ABC scores higher or
equal to 30%, whereas patients with ABC score reduction rates of
less than 30% were classiﬁed as non-responders.

Serum Prolactin Measurement
A fasting morning blood sample was analyzed with a
chemiluminescent immunoassay system (IMMULITE1000,
Siemens Healthcare Diagnostics Products Ltd., Erlangen,
Germany) at the Yuwaprasart Waithayopathum Child and
Adolescent Psychiatric Hospital, Thailand.

Genetic Risk Score
We created an algorithm to describe haplotypes with genetic risk
scores. For protein expression affecting the prolactin level, the
alleles DRD2 Taq1A, -141C indel, and -241A>G had values of 1
assigned for a high-expression allele (A2, Cin, G) and 0.5 for a
low-expression allele (A1, Cdel, A) (Arinami et al., 1997; Jonsson
et al., 1999; Nyman et al., 2009). The score of each haplotype was
the sum of the values assigned to each allele. A high risk score
indicated a high prolactin level.

Plasma Drug Assay
Steady-state plasma concentrations of risperidone and 9-OHrisperidone were quantiﬁed, between 8:00 and 10:00 AM,
approximately 12 h after the bedtime dose, using a validated
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TABLE 1 | Patient demographics (n  124).
Clinical information
Age (years)
Males, n (%)
Daily risperidone dosage (mg/day)
Risperidone treatment duration (months)
Risperidone monotherapy, n (%)
Prolactin level (ng/ml)
RIS level (ng/ml)
9-OH-RIS level (ng/ml)
Active moiety level (ng/ml)
Ratio of risperidone/9-OH-RIS
RIS C/D (ng/ml/mg)
9-OH-RIS C/D (ng/ml/mg)
Active moiety C/D (ng/ml/mg)

value (NPV), and accuracy of the association between serum cutoff value of serum prolactin levels and status of risperidone
response were analyzed using MedCalc (https://www.medcalc.
org/calc/diagnostic_test.php).

Median (IQR)
8.00 (5.00–12.00)
105 (84.68)
0.75 (0.50–1.00)
37.94 (11.01–94.05)
74 (59.68)
15.70 (8.85–22.85)
0.51 (0.14–1.41)
5.28 (2.94–9.29)
6.11 (3.44–11.63)
0.09 (0.03–0.21)
0.71 (0.22–2.03)
7.72 (4.94–12.04)
9.06 (5.82–13.14)

RESULTS
Clinical Characteristics
Our sample cohort consisted of 124 children and adolescents with
a mean age of 8.81 years (SD  4.04). All patients were diagnosed
with ASD and treated with risperidone. Seventy-four patients
(59.68%) received risperidone monotherapy. The remaining
patients received concomitant medications that did not affect
cytochrome P450 2D6 metabolite and prolactin levels.
Demographic data are summarized in Table 1.

RIS, risperidone; 9-OH-RIS, 9-hydroxy-risperidone; Active moiety, the sum of RIS plus 9OH-RIS; C/D, dose-corrected concentration; IQR, interquartile range [quartile 1 (Q1) and
quartile 3 (Q3)].

Association Between Genetic Variations,
Serum Prolactin Levels, and Response to
Risperidone

Statistical Analysis
Statistical analyses were carried out using SPSS v24 for Windows
(IBM, Armonk, NY, United States). Statistical signiﬁcance is
reported as p < 0.05 for a two-tailed distribution. Descriptive
analyses were performed for the sociodemographic variables.
Data are expressed as mean (standard deviation; SD) or
median (interquartile range; IQR) in normal or non-normal
distribution data, respectively. Parametric analysis of variance
(comparisons between more than two groups) and Student’s
t-test (comparisons between two groups) were used to assess
at each time point the association between prolactin or drug levels
and the genotypes. The nonparametric Kruskal-Wallis
(comparisons among more than two groups) and MannWhitney (comparisons between two groups) tests were used to
assess the association between prolactin or drug levels and the
genotypes at each time point. The nonparametric Spearman rank
correlation test was used to measure the correlation between
serum prolactin level and plasma drug level. Because nine
variants were tested, the p-value signiﬁcance threshold was
adjusted for multiple comparisons. Bonferroni’s correction was
applied to adjust for multiple comparisons. According to
Bonferroni’s procedure, the corrected p-values were calculated
by multiplying the p-values by 9 for the numbers of variants. The
signiﬁcance threshold of the corrected p-values was set as 0.05 (Yi
et al., 2014). The Hardy-Weinberg equilibrium, allele, and
genotype frequencies of all candidate SNPs were analyzed
using Haploview v4.2 (Broad Institute, Cambridge, MA,
United States). PHASE v2.1.1 was used to reconstruct
haplotype pairs on the same chromosome (Stephens and
Scheet, 2005). Fisher’s exact test was used to compare the
difference in patient characteristics between responders and
non-responders in children and adolescents with ASD.
Differences in serum prolactin levels between the DRD2
diplotypes were assessed by analysis of covariance
(ANCOVA), controlling for plasma drug level as a covariate.
Receiver operating characteristic (ROC) curves were analyzed
and plotted. Performance parameters such as sensitivity,
speciﬁcity, positive predictive value (PPV), negative predictive

Frontiers in Pharmacology | www.frontiersin.org

Genotype frequencies of the tested polymorphisms are shown in
Supplementary Table S1. Considering codominant, dominant,
and recessive genetic models, there were no differences in serum
prolactin levels for DRD2/ANKK1 Taq1A A2>A1, DRD2 -141C
indel, DRD2 -241A>G, HTR2A-1438G>A, HTR2C -759C>T,
PRL g.13096T>A, PRLR g.163444A>C, and the number of
variable tandem repeats of DAT and 5-HTTLPR.
Haplotypes were constructed using three SNPs of DRD2 on
chromosome 11 (DRD2/ANKK1 Taq1A A2/A1, DRD2 -141C
indel, and -241A>G) with PHASE v2.1.1. Six haplotypes with
minor allelic frequencies of >1% were identiﬁed. The four main
haplotypes were A2-Cin-A (H1), A1-Cin-A (H2), A2-Cin-G
(H3), and A2-Cdel-A (H4), accounting for 91.4% of the
observations (Table 2). Fifteen diplotypes accounted for 99.2%
of the observations (Table 3). We compared the association of
each pair of diplotype groups. Participants with the H1/H3
diplotype showed signiﬁcantly higher prolactin levels than
those of other diplotypes (23.00 ng/ml, p < 0.05).
We created an algorithm to describe a haplotype with a
genetic risk score based on DRD2 expression of protein
affecting the prolactin level. Forty-ﬁve (36.29%) patients
had a common risk score of 4.5 and had a median prolactin
level of 16.60 ng/ml. We compared the common risk score and
found that prolactin levels in patients with a common genetic

TABLE 2 | DRD2 haplotype frequencies predicted by computational phasing
using PHASE v2.1.1.
Type

Haplotype

Observation (n = 124)

H1
H2
H3
H4
H5
H6

A2-Cin-A
A1-Cin-A
A2-Cin-G
A2-Cdel-A
A1-Cdel-A
A1-Cin-G

86
75
35
31
11
10

Frequency (%)
34.68
30.24
14.11
12.50
4.44
4.03

Haplotype presented as DRD2/ANKK1 Taq1A, DRD2 -141C indel, and DRD2 -241A>G.

4

October 2021 | Volume 12 | Article 743494

Hongkaew et al.

Pharmacogenomics, Prolactin Level and Risperidone Response

TABLE 3 | Associations between DRD2 gene diplotypes and serum prolactin levels.
Types

H2/H6
H3/H3
H2/H5
H1/H3
H3/H5 or H4/H6
H1/H5 or H2/H4
H1/H4
H3/H4
H1/H6 or H2/H3
H1/H2
H1/H1
H4/H5
H2/H2

Diplotypes

Observation (n = 124)

Percent (%)

Genetic risk
score

Prolactin levels
(ng/ml)

A1/A1-Cin/Cin-A/G
A2/A2-Cin/Cin-G/G
A1/A1-Cin/Cdel-A/A
A2/A2-Cin/Cin-A/G
A2/A1-Cin/Cdel-A/G
A2/A1-Cin/Cdel-A/A
A2/A2-Cin/Cdel-A/A
A2/A2-Cin/Cdel-A/G
A2/A1-Cin/Cin-A/G
A2/A1-Cin/Cin-A/A
A2/A2-Cin/Cin-A/A
A2/A1-Cdel/Cdel-A/A
A1/A1-Cin/Cin-A/A

4
3
3
12
4
17
14
2
17
23
14
1
10

3.23
2.42
2.42
9.68
3.23
13.71
11.29
1.61
13.71
18.55
11.29
0.81
8.06

4.5
6
3.5
5.5
4.5
4
4.5
5
5
4.5
5
3.5
4

29.40 (15.65–67.70)
28.20 (16.00–29.75)
25.90 (21.80–31.15)
23.00 (17.50–35.25)a,b,c,d
16.90 (13.15–25.30)
16.80 (12.15–21.80)a
16.25 (10.10–24.00)
14.40 (8.00–20.80)
13.30 (7.50–21.40)b
13.00 (7.80–19.40)c
13.00 (9.10–24.00)
12.40
10.60 (7.40–21.80)d

Diplotype presented as DRD2/ANKK1 Taq1A, DRD2 -141C indel, and DRD2 -241A>G.
a
Signiﬁcant at p  0.042 when compared between H1/H3 and H1/H5 or H2/H4.
b
Signiﬁcant at p  0.028 when compared between H1/H3 and H1/H6 or H2/H3.
c
Signiﬁcant at p  0.014 when compared between H1/H3 and H1/H2.
d
Signiﬁcant at p  0.038 when compared between H1/H3 and H2/H2.

TABLE 4 | Associations between genetic risk scores for DRD2 gene haplotypes and serum prolactin levels.
Genetic
risk
score
3.5
4
4.5
5
5.5
6

Diplotypes

Types

N (%)
(n = 124)

Prolactin levels
(ng/ml)

p-value

H2/H5, H4/H5
H1/H5 or H2/H4, H2/H2
H1/H2, H1/H4, H2/H6, H3/H5 or
H4/H6
H1/H1, H1/H6 or H2/H3, H3/H4
H1/H3
H3/H3

A1/A1-Cin/Cdel-A/A, A2/A1-Cdel/Cdel-A/A
A2/A1-Cin/Cdel-A/A, A1/A1-Cin/Cin-A/A
A2/A1-Cin/Cin-A/A, A2/A2-Cin/Cdel-A/A, A1/A1-Cin/Cin-A/G, A2/
A1-Cin/Cdel-A/G
A2/A2-Cin/Cin-A/A, A2/A1-Cin/Cin-A/G, A2/A2-Cin/Cdel-A/G
A2/A2-Cin/Cin-A/G
A2/A2-Cin/Cin-G/G

4 (3.23)
27 (21.77)
45 (36.29)

21.80 (15.05–31.15)
12.70 (8.00–21.60)
16.60 (9.00–22.70)

0.231
0.504
Reference

33 (26.61)
12 (9.68)
3 (2.42)

13.00 (8.00–21.40)
23.00 (17.50–35.25)
28.20 (16.00–29.75)

0.498
0.033a
0.413

Diplotype presented as DRD2/ANKK1 Taq1A, DRD2 -141C indel, and DRD2 -241A>G respectively as follow: high expression allele (A2, Cin, G)  1 and low expression allele (A1, Cdel, A) 
0.5. A high-risk score assumed a high prolactin level.
a
Signiﬁcant at p < 0.05.

risk score of 4.5 (n  45, 36.29%) were signiﬁcantly lower than
those with a genetic risk score of 5.5 (n  12, 9.68%) (16.60 vs.
23.00 ng/ml, p  0.033). Thus, higher DRD2 expression was
related to higher prolactin levels (Table 4). However, there
were high prolactin levels at the lowest and highest risk score
(21.80 ng/ml at a risk score of 3.5 and 28.20 ng/ml at a risk
score of 6, respectively), but there were no signiﬁcant
differences (p > 0.05).
There was no association between any of the interrogated
sequence variations in the candidate pharmacodynamic genes
and the risperidone response (Supplementary Table S2).

Relationships Between Serum Prolactin,
Plasma RIS C/D, 9-OH-RIS C/D, Active
Moiety C/D and Sequence Variations in
Candidate Pharmacodynamic Genes
We conducted ANCOVA to compare the effect of DRD2 diplotypes
on prolactin levels, using RIS C/D, 9-OH-RIS C/D, and active moiety
C/D as covariates to adjust for possible confounding factors. Serum
levels of prolactin were signiﬁcantly higher in the H1/H3 diplotype
group compared with the H1/H2 (Figure 1A; F  5.420, p  0.026),
H1/H5 (Figure 1B; F  4.552, p  0.042), H1/H6 (Figure 1C; F 
4.848, p  0.037), and H2/H2 (Figure 1D; F  5.761, p  0.027)
groups after controlling for plasma drug levels of active moiety C/D.

Relationships Between Serum Prolactin
Levels and Plasma Levels of RIS C/D,
9-OH-RIS C/D, and Active Moiety C/D

Effects of Prolactin in Response to
Risperidone Therapy

Plasma levels of risperidone, 9-OH-risperidone, and the active
moiety were corrected with the daily dose. Serum prolactin levels
were signiﬁcantly correlated among RIS C/D (rs  0.227,
p  0.012), 9-OH-RIS C/D (rs  0.305, p  0.001), and active
moiety C/D (rs  0.343, p < 0.001).
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A total of 124 participants were enrolled in this study; however, only
19 patients were available for naïve and follow-up after being treated
for a minimum of 3 months. The mean age at baseline of the 19
patients was 5.21 years (SD 2.82), and most were male (n  16,
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FIGURE 1 | Relationship between prolactin and active moiety C/D plasma levels in children and adolescents with DRD2 diplotypes of (A) H1/H3 and H1/H2 (p 
0.026), (B) H1/H3 and H1/H5 (p  0.042), (C) H1/H3 and H1/H6 (p  0.037), and (D) H1/H3 and H2/H2 (p  0.027). The black line represents the linear relationship
between prolactin and drug levels in patients carrying an H1/H3 or other diplotype.

84.21%). Table 5 summarizes the ﬁndings for the 19 patients by
responder status according to the percentage decrease in the total
ABC score. Of these, 53% (n  10) responded to risperidone
treatment, whereas 47% (n  9) were non-responders. The mean
age of responders was 5.50 ± 2.84 years and that of non-responders
was 4.89 ± 2.93 years. Median prolactin levels after treatment in nonresponders were higher compared with those in responders (20.10
vs. 10.25 ng/ml, p  0.013). ABC subscale scores after 3 months were
signiﬁcantly lower than those before treatment (paired t-test; p <
0.05). Plasma levels of RIS C/D, 9-OH-RIS C/D, and active moiety
C/D were not signiﬁcantly different between responders and nonresponders. Moreover, there was no signiﬁcant difference in
prolactin levels before and after treatment in responders (7.65 vs.
10.25 ng/ml, p  0.878). In contrast, the prolactin level in nonresponders after risperidone treatment was about twice that in
responders (9.40 vs. 20.10 ng/ml, p  0.028).

ROC curve for prolactin was 0.833 (p  0.014), which was above
the acceptable accuracy level of 0.8. The prolactin cut-off value
with sensitivity and speciﬁcity of 0.5 or greater was
10.25–18.85 ng/ml, with an optimal prolactin cut-off value of
10.9 ng/ml (sensitivity, 100%; speciﬁcity, 60%; PPV, 69.23%;
NPV, 100.00%; highest accuracy, 78.95%). The second
accuracy for serum prolactin levels of 10.25, 12.20, 15.0, and
16.8 ng/ml was 73.68%.

DISCUSSION
Several studies have reported that genetic variation (Young et al.,
2004; Calarge et al., 2009; Yasui-Furukori et al., 2011) or plasma
drug levels of risperidone and its metabolite (Knegtering et al.,
2005; Melkersson, 2006; Ngamsamut et al., 2016) are related to
hyperprolactinemia. However, there are no studies on the
relationship between prolactin elevation and genetic variation,
or whether controlling plasma drug levels of RIS C/D, 9-OH-RIS
C/D, and active moiety C/D can prevent prolactin elevation. The
ﬁndings of the present study suggest that the patients with the
H1/H3 haplotype of DRD2 were at higher risk than patients with

ROC Curve of Serum Prolactin for
Responders
The ROC curve showed that serum prolactin levels predicted the
risperidone response (Figure 2 and Table 6). The area under the
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TABLE 5 | ABC score and serum prolactin levels at baseline and after 3 months of treatment between responders and non-responders (n  19).
Variables

Male, n (%)
Age (years), median (IQR)
Baseline
Body weight (kg), median (IQR)
Risperidone dose (mg/day), median (IQR)
Weight-adjusted dose (mg/kg day), median (IQR)
ABC total score, mean ± SD
ABC-irritability, mean ± SD
ABC-social withdrawal, mean ± SD
ABC-stereotype, mean ± SD
ABC-hyperactivity, mean ± SD
ABC-inappropriate speech, mean ± SD
Prolactin level (ng/ml), median (IQR)
After 3 months
Body weight (kg), median (IQR)
Risperidone dose (mg/day), median (IQR)
Weight-adjusted dose (mg/kg day), median (IQR)
Risperidone duration (months), median (IQR)
ABC total score, mean ± SD
ABC-irritability, mean ± SD
ABC-social withdrawal, mean ± SD
ABC-stereotype, mean ± SD
ABC-hyperactivity, mean ± SD
ABC-inappropriate speech, mean ± SD
Prolactin level, median (IQR), ng/ml
Risperidone, median (IQR), ng/ml
9-OH-RIS, median (IQR), ng/ml
Active moiety, median (IQR), ng/ml
Risperidone C/D, median (IQR), ng/ml
9-OH-RIS C/D, median (IQR), ng/ml
Active moiety C/D, median (IQR), ng/ml

Responders (n = 10)

Non-responders
(n = 9)

p-value

10 (100)
4.50 (4.00–6.00)

6 (66.67)
5.00 (4.00–7.00)

0.087
0.905

17.58 (15.70–25.00)
0.20 (0.20–0.50)
0.01 (0.01–0.01)
85.70 ± 29.73
20.40 ± 8.17
16.80 ± 9.31
9.50 ± 6.08
33.10 ± 8.90
5.90 ± 4.12
7.65 (6.00–17.70)

20.00 (15.30–27.00)
0.25 (0.15–0.50)
0.02 (0.01–0.02)
91.22 ± 26.29
21.89 ± 11.42
22.78 ± 6.80
9.56 ± 5.64
32.44 ± 5.88
4.56 ± 3.32
9.40 (7.10–16.60)

0.968
0.842
0.315
0.675
0.746
0.132
0.984
0.854
0.448
1.000

20.18 (17.00–30.00)
0.50 (0.20–0.60)
0.02 (0.01–0.03)
8.64 (3.00–13.77)
41.50 ± 18.00
7.90 ± 5.26
8.20 ± 3.94
3.40 ± 2.68
18.60 ± 8.21
3.40 ± 2.91
10.25 (6.50–16.00)
0.19 (0.02–0.90)
3.04 (1.67–5.26)
3.86 (1.67–5.56)
23.56 (3.17–40.30)
9.68 (7.12–18.64)
13.58 (9.06–19.42)

23.60 (16.70–32.00)
0.30 (0.20–0.50)
0.01 (0.01–0.02)
4.37 (3.70–7.03)
84.67 ± 14.63
20.78 ± 11.55
19.89 ± 6.90
7.78 ± 5.14
31.44 ± 4.98
4.89 ± 3.55
20.10 (15.80–27.40)
0.33 (0.12–0.58)
4.57 (3.26–7.27)
5.41 (3.28–8.02)
7.19 (3.55–36.12)
8.77 (6.52–15.09)
9.17 (6.77–16.90)

0.905
0.315
0.356
0.780
<0.001
0.011
<0.001
0.041
0.001
0.330
0.013
0.720
0.400
0.447
0.624
0.935
0.638

RIS, risperidone; 9-OH-RIS, 9-hydroxy-risperidone; Active moiety, the sum of RIS plus 9-OH-RIS; C/D, dose-corrected concentration; IQR, interquartile range [quartile 1 (Q1) and quartile 3
(Q3)]; SD, standard deviation.

other diplotypes of presenting with signiﬁcantly higher prolactin
levels with increasing plasma RIS C/D, 9-OH-RIS C/D, and active
moiety C/D. Furthermore, low prolactin levels were associated
with response to risperidone treatment in Thai ASD children and
adolescents.
Hyperprolactinemia is commonly observed in patients treated
with antipsychotics. In our study, 44.35% (55 of 124) of patients
had high prolactin levels, which is a concern for adverse drug
reactions in children and adolescents treated with risperidone.
The reported prevalence of hyperprolactinemia in patients on
risperidone ranges between 44 and 61% (Hongkaew et al., 2015;
An et al., 2016; Bonete Llacer et al., 2019), and abnormal prolactin
levels occur in about 27% of patients taking risperidone (Lally
et al., 2017). Hypothalamic dopamine inhibits prolactin secretion
by acting on dopamine D2 receptors, which inhibits lactotroph
cells (Ben-Jonathan and Hnasko, 2001). Hypothalamic dopamine
inhibits pituitary prolactin secretion and proliferation of
prolactin-producing lactotroph cells by activating lactotroph
dopamine D2 receptors (Ben-Jonathan and Hnasko, 2001;
Fitzgerald and Dinan, 2008). There are several hypotheses for
why prolactin elevation occurs during treatment with certain
antipsychotics. Risperidone may cause high prolactin levels
because of its slow dissociation from dopamine D2 receptors,
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which increases central dopamine D2 receptor occupancy
(Peuskens et al., 2014), resulting in a prolonged blockade and
higher rates of prolactin release. Risperidone is also associated
with weaker blood-brain barrier penetration (Peuskens et al.,
2014) compared with olanzapine and quetiapine (Arakawa et al.,
2010), resulting in greater dopamine D2 receptor occupancy in
the pituitary area, which also increases prolactin levels.
We also investigated whether DRD2 haplotypes are more
informative than each SNP on its own, and the H1/H3
diplotype had the highest serum prolactin levels. These
ﬁndings are consistent with increased prolactin levels in
patients carrying the DRD2/ANKK1 Taq1A A2 or C allele
(Sukasem et al., 2016). These alleles are associated with high
dopamine receptor densities (Jonsson et al., 1999), which may
contribute to blocking dopaminergic activity. DRD2 -241A>G
(rs1799978), which is located in the 5′-promoter region of DRD2,
may contribute to increased expression levels. Data obtained with
lymphoblastoid cell lines suggested that -241G carriers have
higher DRD2 expression levels than non-carriers (Nyman
et al., 2009), which is consistent with our conclusion that
DRD2 -241A>G is involved in hyperprolactinemia. Our results
are also consistent with previous ﬁndings. Calarge et al. (2009)
found that the -241G allele had the largest effect on serum
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higher prolactin level. The increase in prolactin levels with
risperidone can be explained by risperidone inhibiting
dopamine binding to dopamine D2 receptors (Rosenbloom,
2010). The higher the number of dopamine receptors is, the
greater the inhibition by risperidone, and the higher the increase
in prolactin. Thus, high prolactin levels occurred at the highest
risk score of 6. However, this study also observed the high
prolactin level at the lowest risk score of 3.5. This could be
explained by the upregulation of dopamine receptors in patients
with low DRD2 expression and who received long-term
risperidone treatment. Lidow and Goldman-Rakic (1997)
found that 6 months treatment with antipsychotics upregulated
prefrontal and temporal cortical dopamine D2 receptor mRNA
expression in primates. However, there was no signiﬁcant
difference in expression due to the small sample size. The
genetic risk score system is an easy-to-use tool for translating
genotype data into DRD2 expression prediction in a clinical
setting. However, further study is needed to validate this tool.
Because variations in the HTR2A gene (encoding the 5hydroxytryptamine type 2A receptor) and HTR2C gene
(encoding the 5-hydroxytryptamine type 2C receptor)
inﬂuence the binding afﬁnities of antipsychotic medication, in
previous studies, two genetic polymorphisms related to
hyperprolactinemia in schizophrenic patients treated with
classical and/or atypical antipsychotic treatment have been
analyzed. Several studies found contradictory associations
between hyperprolactinemia and HTR2A (Correia et al., 2010;
Ivanova et al., 2017) and HTR2C polymorphisms (Alladi et al.,
2017; Koller et al., 2020). Our study was consistent with a study of
risperidone in 289 Indian schizophrenia patients (Alladi et al.,
2017). They reported no association between HTR2C (−759 C>T)
genetic variants and prolactin levels during risperidone
treatment. Genetic polymorphisms in the promoter region of
the HTR2C gene (−759 C>T) have been investigated in
antipsychotic drug-induced weight gain (Vanwong et al.,
2021). Moreover, transporter and prolactin-related genes
involving the neurotransmitter mechanism of prolactin
secretion were studied. Osmanova et al. (2019) found an
association between two variants in the DAT (SLC6A3) gene
and hyperprolactinemia in the subgroup of patients taking
risperidone/paliperidone in 446 Caucasian schizophrenia
patients. Smith et al. (2004) reported that the short allele of
the 5-HTTLPR indel polymorphism was associated with less of an
increase in prolactin and cortisol than the long/long genotype in
control participants. Lee et al. (2007) found a nominally
signiﬁcant association between PRL and PRLR tagSNPs and
plasma prolactin levels in 95 advanced breast cancer cases.
However, the results were inconsistent because of the different
underlying disease groups and treatments. Thus, until our results
are validated in a prospective study, they should not be applied to
patients with other diseases or undergoing other treatments.
There were no signiﬁcant differences between any genetic
variants selected and responses to risperidone in this study. Thus,
although the DRD2 haplotypes relate to prolactin increase, they
are likely to be predictive for poor markers for treatment
response. Our results agree with Sakumoto et al. (2007), who
found that non-responders without the deletion allele of the

FIGURE 2 | ROC curve analysis showing that serum prolactin level has a
high accuracy (68–78%) for identifying responders and non-responders.

prolactin levels when combined with the Taq1A A1 allele,
whereas Arinami et al. (1997) reported an association between
the DRD2 -141C indel and high DRD2 expression levels in vitro.
Stronger binding of risperidone to dopamine D2 receptors in the
pituitary area is more likely to inhibit dopaminergic activity in
prolactin secretion (Peuskens et al., 2014). Therefore, the ﬁndings
of these studies support our observation that increased DRD2
expression levels, mediated by the DRD2 -141C indel, contribute
to the increase in prolactin levels. Our ﬁnding is also consistent
with a study describing antipsychotic-induced sexual dysfunction
in male schizophrenia, which was attributed to high prolactin
levels in the presence of the DRD2 -141C indel (Zhang et al.,
2011). Therefore, the synergistic effects of the DRD2/ANKK1
Taq1A A2>A1, DRD2 -141C indel, and -241A>G SNPs may be
better captured by the association of haplotypes, rather than
SNPs, with serum prolactin levels. Based on our results, we
suggest that clinicians should perform DNA analysis of the
three SNPs of the DRD2 haplotype as pre-emptive genetic
testing, and prolactin levels should be monitored before and
after 3 months to prevent hyperprolactinemia, especially in
patients with the H1/H3 diplotype.
We developed an algorithm to categorize DRD2 haplotypes
simply according to their DRD2 expression (Arinami et al., 1997;
Jonsson et al., 1999; Nyman et al., 2009). High-expression alleles
(A2, Cin, G) were assigned a score of 1 and low-expression alleles
(A1, Cdel, A) were assigned a score of 0.5. The score of each
haplotype was the sum of the values of each allele. A high risk
score was expected to indicate a high prolactin level. In this study,
a higher DRD2 expression score was signiﬁcantly related to a
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TABLE 6 | Sensitivity, speciﬁcity, and accuracy of prolactin levels predicting risperidone response.
Prolactin levels
(ng/ml)

Sensitivity (%)

Speciﬁcity (%)

PPV (%)

NPV (%)

Accuracy (%)

1.70
3.30
5.20
6.55
8.35
10.25
10.90
12.20
13.60
15.00
15.90
16.80
18.85
20.80
21.85
23.00
25.60
28.80
30.45
31.70

100.00
100.00
100.00
100.00
100.00
100.00
100.00
88.89
77.78
77.78
66.67
66.67
55.56
44.44
44.44
44.44
33.33
22.22
11.11
0.00

0.00
10.00
20.00
30.00
40.00
50.00
60.00
60.00
60.00
70.00
70.00
80.00
80.00
80.00
90.00
100.00
100.00
100.00
100.00
100.00

47.37
50.00
52.94
56.25
60.00
64.29
69.23
66.67
63.64
70.00
66.67
75.00
71.43
66.67
80.00
100.00
100.00
100.00
100.00
-*

-*
100.00
100.00
100.00
100.00
100.00
100.00
85.71
75.00
77.78
70.00
72.73
66.67
61.54
64.29
66.67
62.50
58.82
55.56
52.63

47.37
52.63
57.89
63.16
68.42
73.68
78.95
73.68
68.42
73.68
68.42
73.68
68.42
63.16
68.42
73.68
68.42
63.16
57.89
52.63

PPV, positive predictive value; NPV, negative predictive value.
Bold values represented cut-off value associated with higher and equal 50% in both sensitivity and speciﬁcity.
The italicized value represented the cut-off value associated with higher and equal 50% in both sensitivity and speciﬁcity with the highest degree of accuracy.
*PPV or NPV cannot be estimated.

DRD2 -141C indel showed a higher score for psychiatric,
extrapyramidal, and total side-effects than those with the
deletion allele after 3 weeks of treatment with dopamine
antagonists. The small number of 19 patients in our study
cohort may explain why there were no signiﬁcant differences
among the associations between genetic variants and treatment
response.
Several studies have examined optimizing risperidone dosing
in children and adolescents based on their clinical response
(Research Units on Pediatric Psychopharmacology Autism,
2005; Haas et al., 2009; Pozzi et al., 2016). We found no
signiﬁcant association between plasma drug levels and
risperidone response due to the small sample size, although
non-responders had numerically higher drug plasma levels
than responders, which is consistent with other published
work (Wang et al., 2007; Lostia et al., 2009). However, our
results contradict other studies that show a relationship
between therapeutic drug levels and clinical efﬁcacy (Baumann
et al., 2004; Riedel et al., 2005). This discrepancy may be a result of
the different underlying disease in patients with schizophrenia. In
addition, there may be differences in the timing of the clinical
outcome assessment and the sociodemographic proﬁle of the
patient population among studies. We performed our assessment
at least 3 months into risperidone treatment rather than at
1–6 weeks because prolactin levels in children receiving longterm risperidone tend to peak within the ﬁrst 2 months, and then
steadily decline to values within or close to normal after
3–5 months (Findling et al., 2003). Although we did not
discover an association between plasma drug concentration
and efﬁcacy, the association between plasma drug and serum
prolactin levels remained signiﬁcant. Therefore, monitoring
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risperidone plasma levels may help to prevent adverse drug
reactions, such as hyperprolactinemia.
Although other studies have found that prolactin levels are
inconsistently associated with efﬁcacy (Wang et al., 2007; Lostia
et al., 2009), our study revealed that prolactin levels may induce
changes in neurogenesis, potentially affecting aberrant behaviors
in ASD, consistent with several other studies (Zhang et al., 2002;
Lee and Kim, 2006; Ates et al., 2015). Prolactin is an anterior
pituitary peptide hormone, under inhibitory control by dopamine
released from the tuberoinfundibular dopaminergic neurons
(Grattan, 2015). Because of dopamine regulation of serum
prolactin levels through dopamine D2 receptors in the
hypothalamic-pituitary pathway, the serum prolactin levels
may be a marker of central dopamine function. Risperidone
could induce hyperprolactinemia in excessive dopamine
receptor blockade (Oda et al., 2015) due to its high dopamine
D2 receptor occupancy (68–70%) (Tsuboi et al., 2013), resulting
in hyperprolactinemia in early treatment. Long-term treatment
with antipsychotics could lead to increased dopamine D2
receptor density according to the dopamine supersensitivity
psychosis hypothesis (Oda et al., 2015), and thus could cause
adequate blockade, leading to behavioral improvement. This
hypothesis may explain why some ASD patients had increased
prolactin levels early in risperidone treatment and subsequently
presented with improved symptoms.
The association between high prolactin and worse response could
be explained by the brain/plasma concentration ratio of risperidone.
Arakawa et al. (2010) reported that risperidone showed a slightly
higher brain/plasma concentration ratio. The brain/plasma
concentration ratio was calculated from dopamine D2 receptor
occupancy in the temporal cortex and pituitary, which
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represented the permeability of antipsychotics into the brain. The
brain/plasma concentration ratio of risperidone was 1.61 (Arakawa
et al., 2010), indicating that the risperidone concentration in the
temporal cortex was 1.5-fold greater than that in the pituitary. The
permeability of risperidone into the brain resulted in a higher
concentration in the brain than in plasma. Dopamine D2
receptor occupancy of risperidone in the temporal cortex was
higher than that in the pituitary, causing an improvement in
behaviors and reducing the risk of prolactin elevation. Therefore,
our results suggest that low prolactin levels are an indicator of
response to risperidone, and thus serum prolactin levels could be
used as an indirect biomarker for risperidone response.
The present study is the ﬁrst to report a cut-off value for
prolactin-related poor behavioral responses of children treated
with risperidone of less than 1 mg/day. The prediction of
risperidone response in ASD had an area under the ROC curve
of 0.833. The cut-off point of the prolactin level associated with
sensitivity and speciﬁcity of 0.5 or higher was 10.25–18.85 ng/ml,
and the optimal cut-off value for prolactin of 10.9 ng/ml had the
highest accuracy of 78.95%. We applied the prolactin measurement
as a biomarker for unusual behaviors in patients who did not
respond to risperidone treatment. It might be used as a screening
test to exclude false negatives. When NPV was 100%, meaning that
when the test was negative (low prolactin value), the patient was
responding to treatment, when the PPV was 60%, meaning that
when the test was positive (high prolactin value) of 100 patients,
only 60 patients were not responding to treatment. This
information would be beneﬁcial to health practitioners in clinical
practice. However, further studies are needed to determine the
optimal daily dose of risperidone for prolactin monitoring.
There are several limitations to this study. The small sample
size in the cohort study prevented us from detecting signiﬁcant
genotype-phenotype associations, and thus the results should be
viewed with caution. No relationship was observed for
risperidone dose, weight-adjusted dose, and treatment duration
between responders and non-responders. However, the study
used cohorts under clinical conditions and did not control for
risperidone dose and treatment duration.
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